Monopar Therapeutics Inc. Cash
Monopar Therapeutics Inc. (MNPR) had Cash of $20.01 million as of 2021-12-31, per its 10-K filed 2022-03-24.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2022-03-24
- 2021-12-31: Cash $20.01M.
- 2021-09-30: Cash $21.98M.
- 2021-06-30: Cash $23.84M.
- 2021-03-31: Cash $25.43M.
| Period end | Cash | Cash as first filed |
|---|---|---|
| 2021-12-31 | $20.01M 10-K · filed 2022-03-24 | |
| 2021-09-30 | $21.98M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $23.84M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $25.43M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $16.61M 10-K · filed 2022-03-24 | $1.61M 10-K · filed 2021-03-25 |
| 2020-09-30 | $17.74M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $12.40M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $12.48M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $13.08M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $4.38M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $5.07M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $5.80M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $6.79M 10-K · filed 2020-03-27 | |
| 2018-09-30 | $7.55M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $8.17M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $8.95M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $9.67M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $2.81M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |